Soleo Health Selected As Specialty Pharmacy Partner For ADUHELM™, A New Treatment For Alzheimer’s Disease
FRISCO, Texas, June 16, 2021 – Soleo Health, has been selected as a specialty pharmacy partner for ADUHELM™ (aducanumab-avwa). ADUHELM recently received accelerated approval from the U.S. Food & Drug Administration (FDA) for the treatment of Alzheimer’s disease. Soleo Health will distribute ADUHELM directly to providers and prescribers for patient administration throughout the United States. ADUHELM is the first Alzheimer’s drug to be FDA-approved for treatment in nearly 20 years.
Patients receiving ADUHELM will be supported through Soleo Health’s Alzheimer’s Disease Therapeutic Care Management Center staffed with specially trained interdisciplinary teams comprising highly experienced therapy-care pharmacists, registered nurses and patient care specialists. Our Alzheimer’s TCMC will be supported through our 20 specialty pharmacy locations nationwide with pharmacy licensure in all 50 states.
Drew Walk, Soleo Health’s chief executive officer, stated: “This opportunity allows us to positively impact care and support for Alzheimer’s patients, families, caregivers and the community. With the recent approval of ADUHELM, we are proud to be among a select number of specialty pharmacy partners to help coordinate care with patients, providers and prescribers who may benefit from this novel treatment.”
For more information about ADUHELM™ therapy and services through Soleo Health, contact the Alzheimer’s Disease Therapy Care Management Center at 844-960-9090 or via email: firstname.lastname@example.org.
About ADUHELM™ (aducanumab-avwa)
ADUHELM (aducanumab-avwa), a human monoclonal antibody, is the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain. ADUHELM is indicated for the treatment of Alzheimer’s disease. This indication is granted under accelerated approval based on reduction in amyloid beta plaques in patients treated with ADUHELM. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).
IMPORTANT SAFETY INFORMATION
What is the most important information a patient should know about ADUHELM?
ADUHELM can cause serious side effects including: Amyloid Related Imaging Abnormalities or “ARIA”. ARIA is a common side effect that does not usually cause any symptoms but can be serious. It is most commonly seen as temporary swelling in areas of the brain that usually resolves over time. Some people may also have small spots of bleeding in or on the surface of the brain with the swelling. Although most people with swelling in areas of the brain do not have symptoms, some people may have symptoms such as: headache, confusion, dizziness, vision changes, and nausea. The patient’s healthcare provider will do magnetic resonance imaging (MRI) scans before and during treatment with ADUHELM to check for ARIA.
Patients should call their healthcare provider or go to the nearest hospital emergency room right away if they have any of the symptoms listed above.
Before receiving ADUHELM, patients should tell their healthcare provider about all of their medical conditions, including if: they are pregnant or plan to become pregnant or are breastfeeding or plan to breastfeed. It is not known if ADUHELM will harm their unborn baby or if aducanumab-avwa (the active ingredient in ADUHELM) passes into breast milk.
What are the possible side effects of ADUHELM? ADUHELM can cause serious side effects, including: See above “What is the most important information a patient should know about ADUHELM?”
Serious allergic reactions. Swelling of the face, lips, mouth, or tongue and hives have happened during an ADUHELM infusion. Patients should tell their healthcare provider if they have any of the symptoms of a serious allergic reaction during or after an ADUHELM infusion.
The most common side effects of ADUHELM include: swelling in areas of the brain, with or without small spots of bleeding in or on the surface of the brain (ARIA); headache and fall. Patients should call their healthcare provider for medical advice about side effects. Patients may report side effects to FDA at 1-800-FDA-1088.
About Soleo Health
Frisco, Texas-based Soleo Health is an innovative national provider of complex specialty pharmacy and infusion services administered in the home or at alternate sites of care.
Soleo Health’s interdisciplinary team, comprised of experienced clinical pharmacists and registered nurses, utilizes a consistent patient management process, which leads to quantifiable clinical and economic value while improving the patient experience.
Soleo Health operates 20 locations throughout the U.S. with national nursing coverage and pharmacy licensure in 50 states and is accredited by URAC and The Joint Commission. For more information, visit www.soleohealth.com or connect with Soleo Health on LinkedIn, Facebook and Twitter.